¿Cuál es el fundamento de las terapias basadas en la utilización de células t modificadas (car- t-cells)?

Article Sidebar

PDF (Spanish)

Main Article Content

Aída E. Sterin Prync
Profesora Titular de Biotecnología, Carrera de Bioquímica. Departamento de Bioquímica Aplicada. Instituto Universitario del Hospital Italiano

Downloads

##plugins.themes.bootstrap3.displayStats.noStats##
Published: 2018-09-30
DOI: https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v38i3.569

Article Details

Issue

Vol. 38 No. 3 (2018): Revista del Hospital Italiano de Buenos Aires

Section

Ask the expert
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

1.
Sterin Prync AE. ¿Cuál es el fundamento de las terapias basadas en la utilización de células t modificadas (car- t-cells)? Rev Hosp Ital B.Aires [Internet]. 2018 Sep. 30 [cited 2026 Jul. 31];38(3):119-21. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/569

References

Billingham RE, Brent L, Medawar PB. Quantitative Studies on Tissue Transplantation Immunity. II. The Origin, Strength and Duration of Actively and Adoptively Acquired Immunity. Proc R Soc London. 1954; 143(910):58-80.

Smyth MJ. Multiple approaches to immunotherapy - the new pillar of cancer treatment. Immunol Cell Biol. 2017; 95(4):323-324.

Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507–17.

Brentjens RJ, Davila ML, Riviere I, et al. D19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38.

Tran E, Longo DL, Urba WJ, et al. A Milestone for CAR T Cells. N Engl J Med 2017; 377:2593-2596